Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Galmed Pharmaceutica (GLMD)

Galmed Pharmaceutica (GLMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,516
  • Shares Outstanding, K 25,084
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,770 K
  • 60-Month Beta 2.17
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.52
Trade GLMD with:

Options Overview

Details
  • Implied Volatility 90.45%
  • Historical Volatility 47.50%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 821.47% on 10/12/20
  • IV Low 90.45% on 04/19/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 41
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 802
  • Open Int (30-Day) 652

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate -0.44
  • Number of Estimates 2
  • High Estimate -0.43
  • Low Estimate -0.45
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -51.72%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.03 +4.62%
on 04/16/21
4.07 -22.11%
on 03/22/21
-0.75 (-19.13%)
since 03/19/21
3-Month
3.03 +4.62%
on 04/16/21
6.25 -49.28%
on 02/11/21
-0.58 (-15.47%)
since 01/19/21
52-Week
2.96 +7.09%
on 11/10/20
6.29 -49.60%
on 07/15/20
-1.60 (-33.54%)
since 04/17/20

Most Recent Stories

More News
Thinking about buying stock in Leap Therapeutics, Galmed Pharmaceuticals, Livexlive Media, Catalyst Pharmaceuticals, or Oramed Pharmaceuticals?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LPTX, GLMD, LIVX, CPRX, and ORMP.

LIVX : 3.54 (-0.84%)
LPTX : 1.5900 (+1.27%)
CPRX : 4.31 (+1.16%)
GLMD : 3.17 (+3.26%)
ORMP : 8.79 (+3.90%)
Galmed Pharmaceuticals: Q4 Earnings Snapshot

TEL AVIV, Israel (AP) _ Galmed Pharmaceuticals Ltd. (GLMD) on Thursday reported a loss of $10.3 million in its fourth quarter.

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2020 Financial Results

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™,...

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals Ltd. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 18, 2021 / Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 18, 2021...

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals Announces Dosing of First Subject in First in Human Phase 1 Trial of Amilo-5MER

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company today announced the treatment of the first subject in the First-in-Human...

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2020 Financial Results and Provide Business Update on Thursday March 18

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramchol, a liver targeted, oral, SCD1...

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals Announces Pricing of $10 Million Public Offering of Ordinary Shares

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced the...

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals Announces Proposed Offering of Ordinary Shares

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced that...

GLMD : 3.17 (+3.26%)
Galmed Pharmaceuticals Announces Upcoming Publication in JHEP Reports of New Data Supporting Aramchol's Novel Anti-Fibrotic Mechanism of Action

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, today announced upcoming...

GLMD : 3.17 (+3.26%)
Galmed Hosting KOL Symposium and Pipeline Update

, /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory diseases, announced today that...

GLMD : 3.17 (+3.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing therapies for liver diseases and gallstones. Galmed Pharmaceuticals Ltd. is based in Tel Aviv, Israel.

See More

Key Turning Points

3rd Resistance Point 3.33
2nd Resistance Point 3.25
1st Resistance Point 3.21
Last Price 3.17
1st Support Level 3.09
2nd Support Level 3.01
3rd Support Level 2.97

See More

52-Week High 6.29
Fibonacci 61.8% 5.02
Fibonacci 50% 4.63
Fibonacci 38.2% 4.23
Last Price 3.17
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar